This market resolves to Yes if a peer-reviewed study does confirm a connection between cardiovascular-kidney-metabolic (CKM) syndrome and increased cancer risk by June 30, 2026. This is in light of new findings suggesting a possible link between CKM syndrome and cancer risk.